Latest KRMD news and sentiment

KORU Medical Systems (NASDAQ:KRMD) surpassed revenue expectations in its recent quarterly report, though its stock saw a 14% drop. Analysts maintained their revenue forecasts for 2026 at US$48.1m, an expected 6.6% increase, but modestly raised loss-per-share forecasts to US$0.047. Despite these adjustments, the consensus price target of US$6.60 remains unchanged, indicating analysts believe the company is performing as expected with long-term growth prospects outperforming the industry.

Published

8 Aug 2026 13:48

Provider record

alphavantage, google_news

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems (NASDAQ:KRMD) surpassed revenue expectations in its recent quarterly report, though its stock saw a 14% drop. Analysts maintained their revenue forecasts for 2026 at US$48.1m, an expected 6.6% increase, but modestly raised loss-per-share forecasts to US$0.047. Despite these adjustments, the consensus price target of US$6.60 remains unchanged, indicating analysts believe the company is performing as expected with long-term growth prospects outperforming the industry.

Published

8 Aug 2026 13:41

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems (NASDAQ:KRMD) surpassed revenue expectations in its recent quarterly report, though its stock saw a 14% drop. Analysts maintained their revenue forecasts for 2026 at US$48.1m, an expected 6.6% increase, but modestly raised loss-per-share forecasts to US$0.047. Despite these adjustments, the consensus price target of US$6.60 remains unchanged, indicating analysts believe the company is performing as expected with long-term growth prospects outperforming the industry.

Published

8 Aug 2026 08:00

Provider record

alphavantage, google_news

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Analysts have slightly reduced the 12-month average price target for KORU Medical Systems, Inc. (KRMD) stock from $6.8 to $6.6, implying a 60% potential upside based on the Aug. 5 closing price. The consensus rating among 5 analysts remains a "Buy," with 4 analysts recommending Buy and 1 recommending Hold.

Published

6 Aug 2026 18:39

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems reported better-than-expected earnings and revenue for Q2 2026, with adjusted EPS of $0.02 and revenue of $12.0 million. Despite the beat, shares fell after hours due to reduced full-year revenue guidance and slower international expansion. The company achieved positive net income for the first time since 2019 and remains focused on strategic growth pillars including domestic expansion, international market penetration, and pharmaceutical partnerships, though it shifted its U.S. oncology strategy for PHESGO.

Published

6 Aug 2026 02:40

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems, Inc. (KRMD) published a slide deck in conjunction with their Q2 2026 earnings call. This presentation provides details related to their financial results for the second quarter of 2026. The article was written by SA Transcripts, which is responsible for publishing thousands of quarterly earnings call transcripts.

Published

6 Aug 2026 00:40

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems reported strong second-quarter 2026 financial results, with net revenues growing 18% to $12.0 million and net income improving 222% to $0.25 million. The company updated its full-year 2026 guidance, projecting revenues between $47.5 - $48.5 million and positive adjusted EBITDA. Key strategic moves included acquiring a connected monitoring technology asset and shifting its U.S. oncology market entry focus.

Published

5 Aug 2026 20:40

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

4 Aug 2026 14:49

Provider record

yfinance

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems, Inc. (NASDAQ: KRMD) filed a Form 144 with the SEC on August 3, 2026, indicating a proposed sale of securities. The filing details the acquisition of 75,000 shares of common stock through a restricted stock award on July 28, 2025, which are to be sold via Stifel Nicolaus & Company Inc. The aggregate market value of the securities to be sold is $108,629.00.

Published

4 Aug 2026 03:11

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

This article identifies three promising penny stocks with market caps up to $200 million: KORU Medical Systems (KRMD), Planet Image International (YIBO), and Zevia PBC (ZVIA). Despite a recent drop in the U.S. market, these companies exhibit potential for growth, robust financial health, and manageable debt, making them attractive to investors looking for value. The analysis highlights their latest financial results, market positions, and growth prospects, emphasizing that while they are currently unprofitable, they possess strong liquidity and experienced management.

Published

30 Jul 2026 17:39

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems, a leading medical technology company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. Management will present on August 12, 2026, at 10:00 am ET, and interested parties can access the webcast via the company's investor relations website. KORU Medical specializes in patient-centric large volume subcutaneous infusion solutions, including the Freedom Syringe Infusion System.

Published

30 Jul 2026 14:09

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

2 consolidated

BlackRock, Inc. has filed a Schedule 13G disclosing a 5.6% beneficial ownership stake in KORU Medical Systems (KRMD), amounting to 2,575,761 shares of common stock. The filing indicates BlackRock has sole voting power over 2,537,482 shares and sole dispositive power over all 2,575,761 shares. This passive investment is held in the ordinary course of business, not for the purpose of changing or influencing control of KORU Medical Systems.

Published

29 Jul 2026 20:41

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

First Light Asset Management LLC reduced its stake in KORU Medical Systems, Inc. ($KRMD) by 10.5% in the first quarter, selling over 442,000 shares but still owning 8.2% of the company. Despite this reduction, institutional investors collectively hold 58.6% of KORU Medical Systems, with several firms increasing their positions and insider buying also noted. The stock holds a "Moderate Buy" consensus rating from analysts, with a target price of $7.25.

Published

27 Jul 2026 09:42

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Kaskela Law LLC has announced an investigation into KORU Medical Systems, Inc. (KRMD) on behalf of its current shareholders. The investigation aims to determine if the company or its officers violated securities laws or breached fiduciary duties related to recent corporate actions. Long-term shareholders are encouraged to contact Kaskela Law for more information regarding their legal rights and options.

Published

22 Jul 2026 22:10

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems (NASDAQ: KRMD) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. KORU Medical specializes in developing and commercializing subcutaneous infusion solutions.

Published

18 Jul 2026 14:09

Provider record

alphavantage

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

16 Jul 2026 22:38

Provider record

snapshot

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

KORU Medical Systems, Inc. announced it would report its second quarter 2026 financial results on Wednesday, August 5, 2026. This will be followed by a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. The company specializes in subcutaneous infusion solutions, including the Freedom Syringe Infusion System, and also provides products for biopharmaceutical companies in clinical trials.

Published

15 Jul 2026 23:11

Provider record

alphavantage, archive

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

2 consolidated

Published

15 Jul 2026 12:05

Provider record

snapshot

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

2 Jul 2026 21:21

Provider record

snapshot

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

25 Jun 2026 07:12

Provider record

snapshot

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated